ClinicalTrials.gg
Not yet recruitingNCT07740603Updated Nov 20, 2026

Study of CD38 and CD56 in Chronic Myeloid Leukemia

An observational study in Chronic Myeloid Leukemia (CML), sponsored by Sohag University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Sohag University · Observational

How we know

Updated Nov 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Sex
All
01

Study summary

Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow.

The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.

02

Conditions studied

  • Chronic Myeloid Leukemia (CML)
03

In context

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.

This study's planned enrollment of 200 is above the median of 135 across 148 observational studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Lead sponsor

Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients in sohag city

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with chronic myeloid leukemia

Exclusion criteria

Exclusion Criteria:

  • other hematological diseases
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • chronic myeloid leukemia group

    Diagnostic Test: cd 38 and cd 56

  • healthy group

Interventions

  • Diagnostic testcd 38 and cd 56

    prescence of high percentage of cd38 and cd 56

06

What researchers measure

Primary outcomes

  1. an increased change in cd 38 and cd 56 in chronic leukemic patients

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2027, 5 months later.

Of 45 non-industry observational studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 142. This study's planned 5 months is below that.

Counting every sponsor, half of 67 studies reached it within 53 months; a quarter within 39 and three quarters within 103.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2026
First posted
Jul 31, 2026
StartEst.
Dec 15, 2026was Sep 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Dec 15, 2026
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Start date Sep 1, 2026→Dec 15, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07740603
Lead sponsor
Sohag University
Responsible party
Mennatallah Mostafa Zaki (Resident, Sohag University) — Principal investigator
First posted
Jul 31, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Menna Mostafa Zaki
Contact
mennazaki133@gmail.com
01152386116
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion